ZambiaTuberculosis profile
Population  2014 16 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.1 (3.1–7.5) 32 (20–48)
Mortality (HIV+TB only) 11 (7.4–16) 72 (47–102)
Prevalence  (includes HIV+TB) 69 (38–110) 436 (241–688)
Incidence  (includes HIV+TB) 64 (44–88) 406 (279–557)
Incidence (HIV+TB only) 38 (25–52) 239 (162–331)
         
Case detection, all forms (%) 59 (43–86)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.3 (0.04–1.2) 8.1 (4.1–14)
MDR-TB cases among notified pulmonary
TB cases
83 (11–330) 530 (270–910)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 12 070   1 709
Pulmonary, clinically diagnosed 15 568    
Extrapulmonary 8 584    
       
Total new and relapse 37 931    
Previously treated, excluding relapses 4 785    
Total cases notified 42 716    
Among 36 222 new and relapse cases:
2 726 (8%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases      
Patients started on MDR-TB treatment ***      
TB/HIV 2014 Number (%)
TB patients with known HIV status 39 763 (93)
HIV-positive TB patients 24 198 (61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 21 929 (91)
HIV-positive TB patients on antiretroviral therapy (ART) 17 611 (73)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (85) 39 899
Previously treated cases, excluding relapse, registered in 2013 (80) 4 984
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (27) 100
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 21
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 20
% Funded domestically 29%
% Funded internationally 63%
% Unfunded 8%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-09 Data: www.who.int/tb/data